Buserelin treatment of cryptorchidism: a randomized, double-blind, placebo-controlled study

What Was Tested

This randomized controlled trial paper looks at hCG (human chorionic gonadotropin) and Buserelin.

The 3 groups of patients were similar before treatment in regard to testicular position, chronological and bone age, height and weight, luteinizing hormone, follicle-stimulating hormone, testosterone, penile size and the volume of the contralateral testis.

Who Took Part

The study group was 3 patients.

By PubMed's age tags, the people studied were infants, young children and children, men only.

The study was double blind, placebo controlled in which patients with cryptorchidism were assigned randomly into 3 groups: buserelin treatment (22), surgical treatment (18) or placebo control group (19).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind hCG (human chorionic gonadotropin) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the hCG (human chorionic gonadotropin) group a baseline to be compared against.

What Was Measured

The 3 groups of patients were similar before treatment in regard to testicular position, chronological and bone age, height and weight, luteinizing hormone, follicle-stimulating hormone, testosterone, penile size and the volume of the contralateral testis.

The subject headings attached to it are Chorionic Gonadotropin, Cryptorchidism, Luteinizing Hormone and Testosterone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of hCG (human chorionic gonadotropin) and Buserelin in 3 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (The Journal of urology), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page and the Buserelin compound page, all human trials.